Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. J. Serisier, P. J. Thompson, H. Greville, J. Kolbe, P. R. Bruinenberg (Brisbane, Perth, Adelaide, Australia; Auckland, New Zealand; Hayward, United States Of America). Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE). Eur Respir J 2011; 38: Suppl. 55, 1928

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Pseudomonas aeruginosa (Pa) antibiotic resistance (AR): Comparison in adults and children with cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Daily tele-monitoring of symptoms and spirometry in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) – A comparative study Source: Annual Congress 2010 - COPD: diagnosis Year: 2010 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Safety of sputum induction (SI) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Systematic review of lung clearance index (LCI) in non-cystic fibrosis (CF), non-primary ciliary dyskinesia (PCD) bronchiectasis (Bx) Source: Virtual Congress 2021 – Bronchiectasis Year: 2021 Indicators of pulmonary exacerbation in adults with cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: New aspects of diagnosis, inflammation and detecting exacerbation Year: 2011 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Diagnostic value of induced sputum (IS) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Small airways structural alterations in usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonia (HP) and chronic bronchiolitis (CB) Source: Eur Respir J 2006; 28: Suppl. 50, 308s Year: 2006 Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Role of the specific airway resistance (sRaw) in 4-6 years fibrosis cistic patients Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004 Monitoring small airways disease (SAD) in cystic fibrosis (CF) Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases Year: 2011 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Intestinal current measurement (ICM) as a new diagnostic test for cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: New aspects of diagnosis, inflammation and detecting exacerbation Year: 2011